Camel Whey-Based Nutraceutical Formula for H. pylori Gastritis & Peptic Ulcers Treatment:

The disease

Since its discovery in 1982, Helicobacter pylori (H. pylori) has attracted dramatic attention from researchers, physicians and pharmaceutical companies due to its ability to cause gastritis, peptic ulcers and gastric and hepatic carcinoma. The infections with H. pylori are considered the most widely spread infections worldwide with an estimated rate of more than 50% of the world population in the developing countries.

Read More

Camel GuardTM: Production of Infant formula enriched with antibodies against diarrheal disease

The disease:

Gastroenteritis, a major health problem in developing countries, is the infection of the digestive system. In 2009, the World Health Organization (WHO) estimated that diarrheal diseases caused by gastroenteritis was ranked third in causes of death in children less than five years old with about 1.7 million deaths every year.

Read More

Novel antimicrobial agents of ferulic acid derivatives for the treatment of infections caused by multi-resistant strains of pathogenic bacteria:

The disease

Nosocomial infections are currently considered the major concern for the medical community worldwide. The Centers for Disease Control and Prevention estimated that around 1.7 million hospital-associated infections, contribute to 99,000 deaths each year. Hospital surveys in Europe demonstrated that two thirds of the 25,000 deaths each year caused by Gram negative bacteria. The problem increases with the emergence of antibiotic resistance among the isolated bacterial causes particularly in Gram negative bacteria which can also extend to infect people outside the hospitals.

Read More

Hemoglobin HbA1c Biosensor:

The need:

HbA1c considered as the most famous biomarker for long term monitoring glycemic status of diabetic people. The prevalence of diabetes is increasing worldwide; hence, it was near 2.8% in 2000 with expectation to reach 4.4% at the end of 2030 costing from 171 million to 350 million in 2030 respectively.

Read More

Acne Research (The one behind SKINUE, Patent 1)

The disease

Acne vulgaris is a one of the most common chronic inflammatory disorders of skin affecting adolescents worldwide. It has been estimated that in USA, more than 40 million people have acne with higher incidence in Africa and Far East areas and of all ethnic groups. The disease is characterized by the development of follicular rash that starts as comedones followed by formation of inflammatory lesions marked initially by suppuration, followed by granulomatous inflammation due to the proliferation of the bacterium Propionibacterium acne and the activation of the neutrophils, and, over time, by fibrosis and scarring. Approximately half of the total human skin microbiome is composed of P. acnes.

Read More

PHENYLBORONIC ACID (Patent 3 )

The disease and treatments currently available:

Cancer is one of the main causes of death in the world. Although significant efforts have been made to find new approaches for treating cancer, the primary treatment options remain surgery, chemotherapy and radiation therapy, either alone or in combination. Surgery and radiation therapy, however, are generally useful only for defined types of cancer. Chemotherapy is the method that is generally useful in treating patients with metastatic cancer or diffuse cancers, such as leukemias. Although chemotherapy can provide a therapeutic benefit, it often fails to result in cure of the disease due to the patient's cancer cells becoming resistant to the chemotherapeutic agent. Due, in part, to the likelihood of cancer cells becoming resistant to a chemotherapeutic agent, such agents are commonly used in combination to treat patients.

Read More